A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

Publication Type:

Journal Article


Clinical breast cancer, Volume 8, Issue 6, p.511-5 (2008)


2008, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Deoxycytidine, Drug Synergism, Female, Fluorouracil, Humans, Middle Aged, Piperazines, Proto-Oncogene Proteins c-kit, Public Health Sciences Division, Pyrimidines, Receptor, Platelet-Derived Growth Factor beta, Receptors, Platelet-Derived Growth Factor


Imatinib mesylate is a potent inhibitor of the Bcr-Abl, c-Kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. On the basis of variable expression of c-Kit and PDGFR in breast cancer and of in vitro data supporting synergy between imatinib and capecitabine, the Southwest Oncology Group conducted a phase II trial of the combination in metastatic breast cancer.